Unknown

Dataset Information

0

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.


ABSTRACT: Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, HS-543, and investigated its effect on cell survival or apoptosis in CML cells bearing Bcr-Abl/T315I (BaF3/T315I) or wild-type Bcr-Abl (BaF3/WT). HS-543 showed anti-proliferative effects in the BaF3/WT cells as well as the BaF3/T315I cells with resistance to Imatinib and strongly inhibited the Bcr-Abl signaling pathway in a dose-dependent manner. Furthermore, it significantly increased the sub G1 phase associated with early apoptosis, with increased levels of cleaved PARP and cleaved caspase-3, as well as the TUNEL-positive apoptotic cells. In addition, we found that HS-543 induced apoptosis with the loss of mitochondrial membrane potential by decreasing the expression of Mcl-1 and survivin, together with increasing that of Bax. In BaF3/T315I xenograft models, HS-543 significantly delayed tumor growth, unlike Imatinib. Our results demonstrate that HS-543 exhibits the induction of apoptosis and anti-proliferative effect by blocking the Bcr-Abl signaling pathway in the T315I-mutated Bcr-Abl cells with resistance to Imatinib. We suggest that HS-543 may be a novel promising agent to target Bcr-Abl and overcome Imatinib resistance in CML patients.

SUBMITTER: Kim SJ 

PROVIDER: S-EPMC4359310 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3681494 | BioStudies
1000-01-01 | S-EPMC2893099 | BioStudies
| S-EPMC3938960 | BioStudies
| S-EPMC4413916 | BioStudies
2017-01-01 | S-EPMC5550844 | BioStudies
1000-01-01 | S-EPMC5833368 | BioStudies
2016-01-01 | S-EPMC4916441 | BioStudies
2014-01-01 | S-EPMC4647898 | BioStudies
2013-01-01 | S-EPMC3568121 | BioStudies
1000-01-01 | S-EPMC5352360 | BioStudies